Mubadala-backed Kelix Bio seals MENA insulin manufacturing deal

The undisclosed deal for DiabTec, struck with Jalphur, gives the firm a MENA manufacturing base, as Kelix Bio continues its acquisition spree.

Dubai-headquartered Kelix Bio, wholly owned by Abu Dhabi’s Mubadala Investment (Mubadala), has completed the acquisition of insulin manufacturer DiabTec, a subsidiary of Ras Al Khaimah-headquartered Julphar, for an undisclosed fee.

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media